This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. S. Vasan, MD
New Delhi, India

Arch Intern Med. 1992;152(5):1090.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

I have read the interesting meta-analysis concerning breast cancer and estrogen replacement therapy conducted by Dupont and Page¹ who have found an overall relative risk of 1.08 (95% confidence interval [CI], 0.96 to 1.2) for breast cancer in women who took 0.625 mg/d or less of conjugated estrogens. The authors also observed that "literature does not permit a definitive conclusion concerning whether breast cancer risk increases with the duration of estrogen replacement therapy." These findings are at variance with the results of another, subsequently published, meta-analysis of the effects of estrogen replacement therapy on breast cancer risk by Steinberg et al.² Using a summary dose response slope, Steinberg et al have calculated the proportional increase in risk of breast cancer for each year of estrogen use across 16 studies. They have found a 30% increase in risk of breast cancer (relative risk, 1.3; 95% CI, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?